Folgen
David A. Liebner, MD
David A. Liebner, MD
Assistant Professor of Internal Medicine and Biomedical Informatics, the Ohio State University
Bestätigte E-Mail-Adresse bei osumc.edu
Titel
Zitiert von
Zitiert von
Jahr
NCCN guidelines insights: soft tissue sarcoma, version 1.2021: featured updates to the NCCN guidelines
M von Mehren, JM Kane, MM Bui, E Choy, M Connelly, S Dry, KN Ganjoo, ...
Journal of the National Comprehensive Cancer Network 18 (12), 1604-1612, 2020
2182020
Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology
M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ...
Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022
1102022
Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases
NL Williams, EJ Wuthrick, H Kim, JD Palmer, S Garg, H Eldredge-Hindy, ...
International Journal of Radiation Oncology* Biology* Physics 99 (1), 22-30, 2017
1092017
MMAD: microarray microdissection with analysis of differences is a computational tool for deconvoluting cell type-specific contributions from tissue samples
DA Liebner, K Huang, JD Parvin
Bioinformatics 30 (5), 682-689, 2014
892014
Thyroid cancer: pathogenesis and targeted therapy
DA Liebner, MH Shah
Therapeutic advances in endocrinology and metabolism 2 (5), 173-195, 2011
812011
TP53 mutational status is predictive of pazopanib response in advanced sarcomas
K Koehler, D Liebner, JL Chen
Annals of Oncology 27 (3), 539-543, 2016
702016
Treatment of ipilimumab induced Graves’ disease in a patient with metastatic melanoma
U Azmat, D Liebner, A Joehlin-Price, A Agrawal, F Nabhan
Case Reports in Endocrinology 2016, 2016
632016
A network model for dispersion of communicable diseases
L Bian, D Liebner
Transactions in GIS 11 (2), 155-173, 2007
592007
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.
SP Chawla, KN Ganjoo, S Schuetze, Z Papai, BA Van Tine, E Choy, ...
Journal of Clinical Oncology 35 (15_suppl), 11000-11000, 2017
482017
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
DS Hong, BA Van Tine, AJ Olszanski, ML Johnson, DA Liebner, T Trivedi, ...
Journal of Clinical Oncology 38 (15_suppl), 102-102, 2020
472020
Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients
CM Cebulla, EM Binkley, R Pilarski, JB Massengill, K Rai, DA Liebner, ...
Ophthalmic genetics 36 (2), 126-131, 2015
462015
The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma
DA Liebner
Journal of Surgical Oncology 111 (5), 622-631, 2015
442015
A multicenter phase II study of nivolumab+/-ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
JL Chen, MR Mahoney, S George, CR Antonescu, DA Liebner, ...
Journal of Clinical Oncology 38 (15_suppl), 11511-11511, 2020
412020
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
DS Hong, BA Van Tine, S Biswas, C McAlpine, ML Johnson, AJ Olszanski, ...
Nature medicine 29 (1), 104-114, 2023
382023
Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition
N Rao, H Iwenofu, B Tang, J Woyach, DA Liebner
Journal of the National Comprehensive Cancer Network 16 (2), 115-121, 2018
312018
Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib
DA Liebner, SA Walston, R Cavaliere, CJ Powers, E Sauvageau, ...
Melanoma research 24 (2), 172-176, 2014
312014
Patterns of major wound complications following multidisciplinary therapy for lower extremity soft tissue sarcoma
ED Miller, X Mo, NT Andonian, KE Haglund, DD Martin, DA Liebner, ...
Journal of surgical oncology 114 (3), 385-391, 2016
252016
Angiosarcoma: a rare malignancy with protean clinical presentations
JT Huntington, C Jones, DA Liebner, JL Chen, RE Pollock
Journal of surgical oncology 111 (8), 941-950, 2015
252015
A randomized, double‐blind, placebo‐controlled, phase II study of regorafenib versus placebo in advanced/metastatic, treatment‐refractory liposarcoma: results from the sarc024 …
RF Riedel, KV Ballman, Y Lu, S Attia, ET Loggers, KN Ganjoo, ...
The Oncologist 25 (11), e1655-e1662, 2020
21*2020
ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma
BA Van Tine, MO Butler, D Araujo, ML Johnson, J Clarke, D Liebner, ...
Annals of Oncology 30, v684-v685, 2019
212019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20